NEW YORK, Feb. 7 - Orchid BioSciences and a unit of Thermo Electron have signed a series of technology agreements to develop and market SNP-based diagnostic tests for point-of-care applications and genotyping products for research.
Terms of the agreements call for Orchid to receive non-exclusive rights from Thermo Electron's Thermo BioStar business to develop, supply, and sell genotyping products that will combine Orchid's SNP-IT genotyping technology with BioStar's OIA biosensor technologies.
The companies also have agreed to co-develop and market SNP-based diagnostic products for point-of-care facilities.
Financial terms of the deals were not disclosed.
"Combining the two should enable us to develop and market highly innovative genotyping products for the research and diagnostics marketplaces," Donald R. Marvin, chief operating officer of Orchid BioSciences and acting general manager of Orchid Diagnostics, said in a statement.
Added Marc Casper, president of Thermo Electron's Life Sciences sector: "Through this partnership, we expect Orchid will be able to develop novel products for the growing number of researchers who want to conduct genotyping studies.
"And perhaps even more significant--together we intend to develop the diagnostic products that for the first time could make it possible for physicians to perform real-time diagnostic tests using medically relevant SNPs."
BioStar's thin-film optics technology, which uses optically coated surfaces and light, is used in a variety of applications, including detecting nucleic acids, proteins, PCR products, and pathogens, the company said.